| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/10/2003 | CA2462644A1 Human and murine cytokine polypeptides |
| 04/10/2003 | CA2462638A1 Methods and compositions for modulating apoptosis |
| 04/10/2003 | CA2462632A1 Introduction of the wlds gene for prevention of axonal degeneration in neurological diseases |
| 04/10/2003 | CA2462628A1 Restricted expression lentiviral vectors |
| 04/10/2003 | CA2462602A1 Double stranded rna as an adjuvant in vaccine compositions |
| 04/10/2003 | CA2462599A1 Storage-stable fibrinogen solutions |
| 04/10/2003 | CA2462596A1 Storage-stable human fibrinogen solutions |
| 04/10/2003 | CA2462593A1 Compositions for oral gene therapy and methods of using same |
| 04/10/2003 | CA2462543A1 Glucagon-like peptides (glp-1) and treatment of respiratory distress |
| 04/10/2003 | CA2462443A1 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/10/2003 | CA2462427A1 Treatment of hepatitis b virus infection with human monoclonal antibodies |
| 04/10/2003 | CA2462424A1 A novel g protein-coupled receptor, gave 10 |
| 04/10/2003 | CA2462306A1 Method, instruments, and kit for autologous transplantation |
| 04/10/2003 | CA2462144A1 Micro-rna molecules |
| 04/10/2003 | CA2462143A1 Genetic sequence related to bone diseases |
| 04/10/2003 | CA2461998A1 Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof |
| 04/10/2003 | CA2461905A1 Combined compositions and methods for tumor vasculature coagulation and treatment |
| 04/10/2003 | CA2461877A1 Method of treatment using ligand-immunogen conjugates |
| 04/10/2003 | CA2461715A1 Proliferation and differentiation of stem cells using extracellular matrix and other molecules |
| 04/10/2003 | CA2461596A1 Method for treating hepatitis c virus infection in treatment failure patients |
| 04/10/2003 | CA2461560A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 04/10/2003 | CA2461292A1 Apo-2 ligand variants and uses thereof |
| 04/10/2003 | CA2461254A1 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same |
| 04/10/2003 | CA2461099A1 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | CA2460916A1 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | CA2460770A1 Diagnosing, treating, and preventing cancer using cables |
| 04/10/2003 | CA2460589A1 Method for treating hepatitis c virus infection in treatment failure patients |
| 04/10/2003 | CA2460261A1 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| 04/10/2003 | CA2460257A1 Methods for diagnosing and treating heart disease |
| 04/10/2003 | CA2455389A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | CA2455225A1 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | CA2438330A1 A method for the early detection of cancer |
| 04/09/2003 | EP1300468A2 TRNA synthetase |
| 04/09/2003 | EP1300467A1 Novel polypeptide and dna thereof |
| 04/09/2003 | EP1300464A1 Fungal cell wall synthesis gene |
| 04/09/2003 | EP1300418A1 Gene regulation by oligopeptides |
| 04/09/2003 | EP1300416A1 Memory-enhancing peptides and the use thereof |
| 04/09/2003 | EP1300158A1 Medicinal compositions for angiogenic therapy |
| 04/09/2003 | EP1300155A1 Enteric preparations containing physiologically active peptides |
| 04/09/2003 | EP1300082A2 Lysin of a bacteriophage of Clostridia spp |
| 04/09/2003 | EP1299727A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 04/09/2003 | EP1299725A2 Herpes zinc finger motifs |
| 04/09/2003 | EP1299724A2 Synthetic peptide for neurological disorders |
| 04/09/2003 | EP1299560A2 Identification and modulation of t helper-1 and t helper-2 cells |
| 04/09/2003 | EP1299548A1 Novel therapeutic molecular variants and uses thereof |
| 04/09/2003 | EP1299546A2 Aminoacyl trna synthetases |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299541A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299536A1 Novel alpha-catenin expressed in heart and testis |
| 04/09/2003 | EP1299535A2 Peptide extended glycosylated polypeptides |
| 04/09/2003 | EP1299533A2 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis |
| 04/09/2003 | EP1299529A2 Conserved diaphanous-related formin autoregulatory domain (dad) |
| 04/09/2003 | EP1299528A1 Human olfactory receptors and genes encoding same |
| 04/09/2003 | EP1299522A2 Alteration of cell membrane |
| 04/09/2003 | EP1299457A1 Mammalion haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof |
| 04/09/2003 | EP1299419A2 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 04/09/2003 | EP1299418A1 Insulin derivatives and synthesis thereof |
| 04/09/2003 | EP1299417A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 04/09/2003 | EP1299416A2 Antifungal and/or antibacterial peptides, preparation methods and composition containing same |
| 04/09/2003 | EP1299415A1 Chemokine receptor modulators, production and use |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299411A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 04/09/2003 | EP1299410A2 GFR alpha1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 04/09/2003 | EP1299377A2 Spla2 inhibitors |
| 04/09/2003 | EP1299348A1 Compounds and compositions for delivering active agents |
| 04/09/2003 | EP1299126A2 Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases |
| 04/09/2003 | EP1299125A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 04/09/2003 | EP1299121A2 Thromboxane receptor antagonist containing formulations for potentiating organic nitrates having vasodilating activity |
| 04/09/2003 | EP1299119A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a ginkgolide compound |
| 04/09/2003 | EP1299114A1 Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |
| 04/09/2003 | EP1299113A2 Use of the heat shock protein gp96 |
| 04/09/2003 | EP1299106A2 Method for treatment and prevention of mastitis |
| 04/09/2003 | EP1299104A1 Tamper-resistant oral opioid agonist formulations |
| 04/09/2003 | EP1299100A1 Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| 04/09/2003 | EP1299091A2 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 04/09/2003 | EP1299087A1 Microspheres and adjuvants for dna vaccine delivery |
| 04/09/2003 | EP1299048A1 Biodegradable vehicles and delivery systems of biologically active substances |
| 04/09/2003 | EP1299032A1 DNA encoding human serine protease D-G |
| 04/09/2003 | EP1189933B1 Echinocandin derivatives, method for preparing the same and application as antifungal agents |
| 04/09/2003 | EP1106624B1 5-membered ring compounds |
| 04/09/2003 | EP1094824A4 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 04/09/2003 | EP1083922B1 Composition and method for treatment of pseudomonas aeruginosa |
| 04/09/2003 | EP1037587B1 Site-specific preparation of polyethylene glycol-grf conjugates |
| 04/09/2003 | EP0998494B1 Pompilid wasp-derived neuropeptides |
| 04/09/2003 | EP0977580B1 MATERIALS AND METHODS RELATING TO INHIBITING THE INTERACTION OF p53 AND mdm2 |
| 04/09/2003 | EP0963197A4 Guanylhydrazones useful for treating diseases associated with t cell activation |
| 04/09/2003 | EP0954524B1 Process for purifying apolipoproteins |
| 04/09/2003 | EP0874641B1 Igf-i and -ii for the treatment of diseases of the central nervous system |
| 04/09/2003 | EP0862440B1 Therapeutic use of hemoglobin in promoting wound healing |
| 04/09/2003 | EP0840748B1 Transforming growth factor beta crystals |
| 04/09/2003 | EP0827396B1 Production scale method of forming microparticles |
| 04/09/2003 | EP0806477B1 Use of a recombinant dna comprising dna coding for smooth muscle-type myosin heavy-chain sm1 isoform protein in the manufacture of a medicament |
| 04/09/2003 | EP0804552B1 Redirection of cellular immunity by receptor chimeras |
| 04/09/2003 | EP0795608B1 Antithrombotic agent and anti-von willebrand factor monoclonal antibodies |
| 04/09/2003 | EP0784685B1 Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor |
| 04/09/2003 | EP0779933B1 Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| 04/09/2003 | EP0768898B1 Cascade-polymer complexes and methods of producing the same |
| 04/09/2003 | EP0723455B1 Method of inhibiting phagocytosis |
| 04/09/2003 | EP0722462B1 Dna encoding prostaglandin receptor ip |